Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RDHL PR was covered on a broader platform in AH: https://www.bizjournals.com/triangle/news/2020/04/13/raleigh-drugmakers-covid-19-treatment-shows-early.html?ana=yahoo&yptr=yahoo
News of the 2 recovered COVID patients is getting spread under a broader public now.
I think the poster calling the 53.51 thing passed away before he got a chance to sell at 3$.. Nevertheless agree with your statement that he was a pumper!
or try following link
https://sci-hub.tw/
Works best if you look up a paper through its DOI number.
Bullshit, I also worked for a big company (telecom sector). They struggled around the dollar mark (euro where I live) for a couple of years due to the crisis. 2 years back they got gobbled up by another telco (former phone manufacturer). Nobody knew about it, no rumors whatsoever, everybody was caught by surprise by the announcement at that time.
Edit: Meant as a reply to Suv... not you
All I can think is that a big fund is buying in again.
I think Leo pays an annual, small, listing fee to keep the application ongoing. I remember it popping it up somewhere in the files (no time to verufy it now though)
Come on.. the guy is a notorious pumper (prob the alter-ego of mr.celgene Dr Jerry). The board is better off without him and his likes ...
Your analysis was spot on Bio!
Hard to compare duration data from S..X to the incidence data from IPIX but here you go:
Patients receiving 1.5 mg/kg of SGX942, a synthetic peptide called an innate defense regulator that modulates the body's reaction to injury and infection, experienced a median reduction in the duration severe OM of 50% (18 days to nine days; p=0.099) while those undergoing the most aggressive CRT showed a median duration reduction of 67% (30 days to 10 days; p=0.040).
Again this is a trial of which the outcomes can vary depending on the patient profiles (especially with a low n like here).
Do you really expect a linear improvement from interim to final results. If you really think that, then you're a tool!
Opinions are formulated once again without any substantiated evidence... How can you know duration results are not good, while bottom line results are still being crunched? I'll tell you: You dont know!!
from the PR: Of the 61 patients randomized, 46 patients met the cumulative radiation dose criteria of at least 55 Gy
Maybe people died in the meantime, couldnt take any more radiation ... all sorts of reasons why the number went to 46 (39 pp).
This is a trial, things like that happen ...
Consider this: 60% of the people did not get severe OM in the bril group!!! Ask them how they feel!
Incidence of OM in the control group went from 70% to 60%
IMO not that high of a difference and due to the expanded n
all by all happy with the results
from the original interim analysis excerpt:
Primary Efficacy Results Incidence of Severe OM (WHO Grade > 3)
• Active Arm (Brilacidin): 2 of 9 patients (22.2 percent)
• Control Arm (Placebo): 7 of 10 patients (70 percent)
Secondary Efficacy Results Duration of Severe OM (WHO Grade > 3)
• Active Arm (Brilacidin): Mean 10.5 days (Range 3 to 18 days; 2 patients)
• Control Arm (Placebo): Mean 14 days (Range 3 to 39 days; 7 patients)
Amen citrati!
53.53 ... can't wait for it to happen ;)
A bit of DD from the 10Q:
SYN-004
- Expect to share additional results regarding several exploratory endpoints from Phase 2b proof-of-concept clinical trial designed to evaluate SYN-004’s (ribaxamase) ability to protect the gut microbiome from opportunistic bacterial infections and prevent the emergence of antimicrobial resistance (AMR) in the gut microbiome (4Q 2017)
- Plan to continue collaborative discussions with the FDA to solidify details and components of the drug development plan and regulatory pathway towards marketing approval for SYN-004 (ribaxamase) (1Q 2018)
- Plan to initiate Phase 3 clinical trial(s) (2018)
Worth mentioning they have BTD designation for SYN-004.
Patience is golden with this one imo.
Same here, in holddown mode for the other one. I agree the PR was nice today. IDRA from the other side has been good for me over the years ;)
Hi Youssef,
Also still buying weekly in the other one (I..X)?
Because it was an open label study. Not sure though.
Anybody else can chime in.
Likewise, don't post much. Did my DD long time ago and comfortable with the company. But the silent majority truly appreciates SOX's posts (and all the others who keep posting their solid DD)
Think Sox meant to be cynical here
No they don't
Because the B franchise does not consist only of 1 compound suitable for treating ABSSII... Offcourse you forgot to mention the numerous other indications which can be treated with B (B-OM, IBD, Diabetic Ulsters,...)
GO IPIX
True that! Leo en co know the exact identity of the whole shorter's group. This is just more evidence piling up. Agree they are so stupid to keep pulling this shit off on the same victi...on and on...
So in all honesty and to keep it balanced, here what Leo also said about RS:
"Hi. I'll take that. I think most shareholders know already or the old shareholders know how I feel. So the short answer is no, no and no. That has not been brought up at any Board of Directors meeting. At least I will vote again it and I'm confident that other Board members would as well."
you guys know how to cherrypick ...
It's not if you live on the other side of the Atlantic ;)
Go IPIX
don't forget pathetic
The target end date you mention is untrue. There was never a hard date mentioned by CTIX management for completion.
There will be a P interim update somewhere in Q3
OT: what is that sentiment indicator next to the price showing up recently?
Based on what metrics does it measure that?
Nice one 8-)
Made me chuckle
Amen... my money which I can afford to lose is in this now. My bets are in, no point in getting trolled by those that didn't have the courage to take profits when it was 5'ish. No point following this board anymore, most is BS and whining nowadays, what was the term again? Schadenfreude? ...
All one can do is ride it out, buy, or sell and move on. Not much good hanging around complaining.
Doing my PhD (in geology) I had one of my articles resubmitted three times: first time rejected by all reviewers, resubmitted a second time I had major revisions, third time I had minor revisions -> time between my first submittal and effective publication: 1,5 years. I can confirm that it takes sometimes months to get an article reviewed, one of the more frustrating things while doing my PhD.
CTIX has never had any ties to Platinum partners as I recall
Apart from an erroneous filing in 2010 which was corrected, never did Dr.Menon claim he had a PhD from Harvard! If you disagree I would advise you take up contact with the Ashcroft lawfirm... Others made this claim already and got burned!
Great news!!
Don't post much here, but me to have been steadily accumulating.
Know that there are many longs here monitoring the board. Although the naysayers/whiners are the most vocal, they are definitely not in the majority!!
Last 8k i see isfrom 08/04. also on edgar no new 8K
Can foreigners also file a complaint? If so I will file one!
What bugs me is that people throw the wildest theories around and are then dissapointed that things don't pan out like they wished it would. I enjoy reading this board, especially the info from some knowledgeable posters but what I won't do is participate in the meaningless discussions what Leo & co should/would/could do! I do own a big stake in this co and did my dd a long time ago (the late bioman brought me here). I just re-evaluate my position everytime new info is available... but for now I just sit back and relax, watching CTIX making progress as time goes by. Goodnight!
Doubt it... delayment due to mfg issues...from the corporate update:
In December, the FDA gave us permission to begin a Phase 2 trial of Prurisol for psoriasis. Subsequently, we have completed GMP manufacturing of Prurisol and placebo, engaged vendors and principal investigators and contracted with sites to begin the trial. We expect enrollment to begin in 2Q 2015. We are engaging the trial at more clinical sites than originally planned and expect to make up for lost time as the manufacturing process took longer then expected. - See more at: http://cellceutix.com/cellceutix-provides-corporate-update/#sthash.1HuCwWvo.dpuf